N-(2,4-Dimethyl-2-pentyl)-methansulfonamid | 60421-41-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-(2,4-Dimethyl-2-pentyl)-methansulfonamid
• 英文别名: N-(2,4-dimethylpentan-2-yl)methanesulfonamide
• CAS: 60421-41-2
• 化学式: C₈H₁₉NO₂S
• 分子量: 193.31
• InChiKey: WFPWZNSXVVRDJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-二甲基-2-戊醇 在 sodium hydroxide 、 氰化钠 作用下， 以 乙醚 、 苯 为溶剂， 生成 N-(2,4-Dimethyl-2-pentyl)-methansulfonamid
  参考文献：
  名称：

  Insertion of sulfonylnitrenes into the carbon-hydrogen bonds of saturated hydrocarbons. Acid-catalyzed thermolysis of N-alkyl sulfonamides

  摘要：

  DOI：

  10.1021/ja00430a043

文献信息

• 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
  申请人：Gruenenthal GmbH

  公开号：US20170197949A1

  公开（公告）日：2017-07-13

  The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

  该发明涉及8-氨基-2-氧代-1,3-二氮杂螺[4.5]癸烷衍生物，它们的制备方法以及它们在医学中的应用，特别是在疼痛治疗中的应用。
• Aryl substituted imidazonaphthyridines
  申请人：Niwas Shri

  公开号：US20070219228A1

  公开（公告）日：2007-09-20

  Imidazonaphthyridine ring systems substituted with an aryl substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明公开了以芳基取代的咪唑萘啉环系统化合物、含有该化合物的制药组合物，以及将这些化合物用作免疫调节剂的方法，用于在动物体内诱导细胞因子的生物合成，并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
• 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
  申请人：Grünenthal GmbH

  公开号：US10793556B2

  公开（公告）日：2020-10-06

  The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

  本发明涉及 8-氨基-2-氧代-1,3-二氮杂-螺-[4.5]-癸烷衍生物、其制备方法及其在医学中的应用，特别是在疼痛治疗中的应用。
• Macrocyclic compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US11053253B2

  公开（公告）日：2021-07-06

  Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  本发明提供了大环补体因子 D 抑制剂、药物组合物及其用途以及制造工艺。所提供的化合物包括式I、式II、式III、式IV、式V、式VI、式VII和式VIII或其药学上可接受的盐、原药、同位素类似物、N-氧化物或分离异构体，可选药学上可接受的组合物。本文所述的抑制剂以因子 D 为靶点，抑制或调节补体级联。
• Agonists of peroxisome proliferator-activated receptor alpha and methods of use
  申请人：The Board of Regents of the University of Oklahoma

  公开号：US11447452B2

  公开（公告）日：2022-09-20

  Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.

  本发明公开了具有过氧化物酶体增殖激活受体α（PPARα）激动活性的苄基衍生物化合物、含有此类化合物的组合物，以及将其用于增强 PPARα 活性以治疗涉及炎症和/或血管生成的疾病和/或病症的方法，特别是眼部疾病和/或病症，如但不限于视网膜炎症、视网膜新生血管、视网膜血管渗漏、早产儿视网膜病变、糖尿病视网膜病变、老年性黄斑变性和糖尿病黄斑水肿。